A comparison of 2 protocols for living-related renal transplantation in children: Donor-specific transfusions versus cyclosporine

M. R. Leone, S. R. Alexander, T. Melvin, J. Striegel, K. Reller, Douglas Norman, John Barry

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We analyzed the results obtained with protocols for immunosuppression of pediatric recipients of halpoidentical living-related renal transplants. In the donor-specific transfusion group transfusion of blood products obtained from the prospective organ donor was performed before transplantation, and at transplantation maintenance immunosuppression of azathioprine and prednisone was begun. In the cyclosporine group donor-specific transfusion was not used, and maintenance immunosuppression of cyclosporine and azathioprine was begun 1 week before transplantation, with the addition of prednisone at transplantation. Of 24 donor-specific transfusion recipients 3 had circulating cytotoxic antibodies to the prospective donor for an incidence of 12%. There was no significant difference between groups with respect to 1-year actual patient and graft survival (100 and 89 versus 100 and 86%, respectively), 1-year mean serum creatinine level (1.1 versus 1.2 mg./dl.), rejection treatments per patient (2.5 versus 2.6) and total days hospitalized during year 1 after transplantation (27 versus 18), with donor-specific transfusion data presented first. Initial hospitalization was significantly shorter (10 versus 16 days, p <0.05) and the incidence of rejection crises within 3 months was significantly less (68 versus 94%, p <0.05) in the cyclosporine group. We believe that cyclosporine and azathioprine pre-treatment of pediatric recipients of haploidentical living-related renal transplants with the addition of prednisolone at transplantation is preferable to a donor-specific transfusion protocol because there is no risk of recipient sensitization to the prospective donor, and patient and graft survival is not adversely affected.

Original languageEnglish (US)
Pages (from-to)721-723
Number of pages3
JournalJournal of Urology
Volume144
Issue number3
StatePublished - 1990

Fingerprint

Kidney Transplantation
Cyclosporine
Tissue Donors
Transplantation
Azathioprine
Immunosuppression
Graft Survival
Prednisone
Maintenance
Pediatrics
Transplants
Kidney
Incidence
Blood Group Antigens
Prednisolone
Blood Transfusion
Creatinine
Hospitalization
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

A comparison of 2 protocols for living-related renal transplantation in children : Donor-specific transfusions versus cyclosporine. / Leone, M. R.; Alexander, S. R.; Melvin, T.; Striegel, J.; Reller, K.; Norman, Douglas; Barry, John.

In: Journal of Urology, Vol. 144, No. 3, 1990, p. 721-723.

Research output: Contribution to journalArticle

Leone, M. R. ; Alexander, S. R. ; Melvin, T. ; Striegel, J. ; Reller, K. ; Norman, Douglas ; Barry, John. / A comparison of 2 protocols for living-related renal transplantation in children : Donor-specific transfusions versus cyclosporine. In: Journal of Urology. 1990 ; Vol. 144, No. 3. pp. 721-723.
@article{0785384c22e14d1588c52377127e37df,
title = "A comparison of 2 protocols for living-related renal transplantation in children: Donor-specific transfusions versus cyclosporine",
abstract = "We analyzed the results obtained with protocols for immunosuppression of pediatric recipients of halpoidentical living-related renal transplants. In the donor-specific transfusion group transfusion of blood products obtained from the prospective organ donor was performed before transplantation, and at transplantation maintenance immunosuppression of azathioprine and prednisone was begun. In the cyclosporine group donor-specific transfusion was not used, and maintenance immunosuppression of cyclosporine and azathioprine was begun 1 week before transplantation, with the addition of prednisone at transplantation. Of 24 donor-specific transfusion recipients 3 had circulating cytotoxic antibodies to the prospective donor for an incidence of 12{\%}. There was no significant difference between groups with respect to 1-year actual patient and graft survival (100 and 89 versus 100 and 86{\%}, respectively), 1-year mean serum creatinine level (1.1 versus 1.2 mg./dl.), rejection treatments per patient (2.5 versus 2.6) and total days hospitalized during year 1 after transplantation (27 versus 18), with donor-specific transfusion data presented first. Initial hospitalization was significantly shorter (10 versus 16 days, p <0.05) and the incidence of rejection crises within 3 months was significantly less (68 versus 94{\%}, p <0.05) in the cyclosporine group. We believe that cyclosporine and azathioprine pre-treatment of pediatric recipients of haploidentical living-related renal transplants with the addition of prednisolone at transplantation is preferable to a donor-specific transfusion protocol because there is no risk of recipient sensitization to the prospective donor, and patient and graft survival is not adversely affected.",
author = "Leone, {M. R.} and Alexander, {S. R.} and T. Melvin and J. Striegel and K. Reller and Douglas Norman and John Barry",
year = "1990",
language = "English (US)",
volume = "144",
pages = "721--723",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A comparison of 2 protocols for living-related renal transplantation in children

T2 - Donor-specific transfusions versus cyclosporine

AU - Leone, M. R.

AU - Alexander, S. R.

AU - Melvin, T.

AU - Striegel, J.

AU - Reller, K.

AU - Norman, Douglas

AU - Barry, John

PY - 1990

Y1 - 1990

N2 - We analyzed the results obtained with protocols for immunosuppression of pediatric recipients of halpoidentical living-related renal transplants. In the donor-specific transfusion group transfusion of blood products obtained from the prospective organ donor was performed before transplantation, and at transplantation maintenance immunosuppression of azathioprine and prednisone was begun. In the cyclosporine group donor-specific transfusion was not used, and maintenance immunosuppression of cyclosporine and azathioprine was begun 1 week before transplantation, with the addition of prednisone at transplantation. Of 24 donor-specific transfusion recipients 3 had circulating cytotoxic antibodies to the prospective donor for an incidence of 12%. There was no significant difference between groups with respect to 1-year actual patient and graft survival (100 and 89 versus 100 and 86%, respectively), 1-year mean serum creatinine level (1.1 versus 1.2 mg./dl.), rejection treatments per patient (2.5 versus 2.6) and total days hospitalized during year 1 after transplantation (27 versus 18), with donor-specific transfusion data presented first. Initial hospitalization was significantly shorter (10 versus 16 days, p <0.05) and the incidence of rejection crises within 3 months was significantly less (68 versus 94%, p <0.05) in the cyclosporine group. We believe that cyclosporine and azathioprine pre-treatment of pediatric recipients of haploidentical living-related renal transplants with the addition of prednisolone at transplantation is preferable to a donor-specific transfusion protocol because there is no risk of recipient sensitization to the prospective donor, and patient and graft survival is not adversely affected.

AB - We analyzed the results obtained with protocols for immunosuppression of pediatric recipients of halpoidentical living-related renal transplants. In the donor-specific transfusion group transfusion of blood products obtained from the prospective organ donor was performed before transplantation, and at transplantation maintenance immunosuppression of azathioprine and prednisone was begun. In the cyclosporine group donor-specific transfusion was not used, and maintenance immunosuppression of cyclosporine and azathioprine was begun 1 week before transplantation, with the addition of prednisone at transplantation. Of 24 donor-specific transfusion recipients 3 had circulating cytotoxic antibodies to the prospective donor for an incidence of 12%. There was no significant difference between groups with respect to 1-year actual patient and graft survival (100 and 89 versus 100 and 86%, respectively), 1-year mean serum creatinine level (1.1 versus 1.2 mg./dl.), rejection treatments per patient (2.5 versus 2.6) and total days hospitalized during year 1 after transplantation (27 versus 18), with donor-specific transfusion data presented first. Initial hospitalization was significantly shorter (10 versus 16 days, p <0.05) and the incidence of rejection crises within 3 months was significantly less (68 versus 94%, p <0.05) in the cyclosporine group. We believe that cyclosporine and azathioprine pre-treatment of pediatric recipients of haploidentical living-related renal transplants with the addition of prednisolone at transplantation is preferable to a donor-specific transfusion protocol because there is no risk of recipient sensitization to the prospective donor, and patient and graft survival is not adversely affected.

UR - http://www.scopus.com/inward/record.url?scp=0025111341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025111341&partnerID=8YFLogxK

M3 - Article

C2 - 2388336

AN - SCOPUS:0025111341

VL - 144

SP - 721

EP - 723

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -